| Name | Title | Contact Details |
|---|
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.
CME was founded in 1978 by psychiatrist John Schwartz, whose vision was to provide high-quality, practical continuing medical education and information for mental health clinicians throughout the United States. In its first decade, CME successfully
Crux Biomedical is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Pennsylvania Health Care Cost Containment Council (PHC4) is an independent state agency responsible for addressing the problem of escalating health costs, ensuring the quality of health care, and increasing access for all citizens regardless of ability to pay.
Scherago International is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.